Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cardiovascular risks associated with protease inhibitors for the treatment of HIV

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Introduction: Cumulative use of some first-generation protease inhibitors has been associated with higher rates of dyslipidemia and increased risk of cardiovascular disease. The protease inhibitors most commonly in use are atazanavir and darunavir, which have fewer detrimental lipid effects and greater tolerability. This paper aims to review the evidence of a potential association of these contemporary protease inhibitors with the risk of ischemic CVD and atherosclerotic markers.Areas covered: We searched for publications of randomized trials and observational studies on PubMed from 1 January 2000 onwards, using search terms including: protease inhibitors; darunavir; atazanavir; cardiovascular disease; cardiovascular events; dyslipidemia; mortality; carotid intima media thickness; arterial elasticity; arterial stiffness and drug discontinuation. Ongoing studies registered on clinicaltrials.gov as well as conference abstracts from major HIV conferences from 2015-2020 were also searched.Expert opinion: Atazanavir and darunavir are no longer part of first-line HIV treatment, but continue to be recommended as alternative first line, second- and third-line regimens, as part of two drug regimens, and darunavir is used as salvage therapy. Although these drugs will likely remain in use globally for several years to come, baseline CVD risk should be considered when considering their use, especially as the population with HIV ages.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Drug Safety
Vol/bind20
Udgave nummer11
Sider (fra-til)1351-1366
Antal sider16
ISSN1474-0338
DOI
StatusUdgivet - nov. 2021

ID: 67940336